IP Library Granted Patent US 10,138,213
Granted Patent B2
US 10,138,213 · App. 14/749,027 · Granted Nov 27, 2018

Stereochemically enriched compositions for delivery of nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,138,213
App. No.
14/749,027
Granted
Nov 27, 2018
Kind
B2
Abstract

Provided, in part, is a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I: a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, the composition characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition: are chemical entities of formula I.a, wherein the first threshold amount is 50%; or are chemical entities of formula I.b.1, wherein the first threshold amount is 25%; or are chemical entities of formula I.b.2, wherein the first threshold amount is 25%, wherein the chemical entities of formula I.a, I.b.1, and I.b.2, are described herein, and methods of using such compositions, for example, for the delivery of a polynucleotide in vivo.

Claims (10)

1. A composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:

a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, wherein

70% or more of the chemical entities of formula I have the structure set forth by formula I.a.i:

2. The composition of claim 1 , wherein 80% or more of the chemical entities of formula I have the structure set forth by formula I.a.i.

3. The composition of claim 2 , wherein 90% or more of the chemical entities of formula I have the structure set forth by formula I.a.i.

4. A lipid nanoparticle comprising the composition of claim 1 and a polynucleotide.

5. The lipid nanoparticle of claim 4 , wherein 80% or more of the chemical entities of formula I have the structure set forth by formula I.a.i.

6. The lipid nanoparticle of claim 4 , wherein said polynucleotide is mRNA.

7. The lipid nanoparticle of claim 4 , further comprising one or more cationic lipids, non-cationic lipids, cholesterol-based lipids, PEG-modified lipids, and/or polymers.

8. The lipid nanoparticle of claim 4 , wherein 90% or more of the chemical entities of formula I have the structure set forth by formula I.a.i.

Assignments (3)
CHANGE OF NAME Recorded Jul 20, 2017
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 043267/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 042177/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2015
From: DEROSA, FRANK; KARVE, SHRIRANG; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 036649/0833 →
Cited By (3)
US 12,239,735 US 12,458,604 US 12,576,040